In a groundbreaking exploration that promises to reshape the understanding of prenatal medication safety, researchers from the University of Nebraska Medical Center (UNMC) have unveiled compelling evidence linking prenatal exposure to certain commonly prescribed medications with an increased risk of autism spectrum disorder (ASD) in children. This comprehensive study, published in the prestigious journal Molecular Psychiatry, harnesses the power of a vast dataset encompassing over six million maternal-child health records from the Epic Cosmos database. This extensive cohort represents roughly one-third of all U.S. births from 2014 through 2023, providing a robust foundation for uncovering subtle but significant associations.
The crux of this pioneering work lies in the identification of a class of medications known to impair sterol biosynthesis—a critical biochemical pathway responsible for cholesterol production and regulation. Unlike prior research efforts that categorized prenatal medications based on their clinical indications, this study adopted a novel approach, grouping drugs by their shared biochemical interference. These sterol biosynthesis-inhibiting medications (SBIMs) include a broad array of drugs commonly prescribed during pregnancy, spanning antidepressants, antipsychotics, anxiolytics, beta-blockers, and statins. Among the 14 SBIMs scrutinized, notable examples include fluoxetine, sertraline, atorvastatin, and propranolol, each prescribed millions of times annually in the United States.
The analysis reveals a striking statistical correlation: pregnant individuals prescribed at least one SBIM faced a 1.47-fold increase in the likelihood of delivering a child later diagnosed with ASD. More alarmingly, this risk escalated in tandem with the number of these medications prescribed. Co-prescription of multiple SBIMs compounded the threat, culminating in a 2.33 times higher risk when four or more such medications were administered simultaneously. The magnitude of these findings demands urgent attention, particularly as prenatal SBIM exposure increased markedly during the nearly decade-long study period, rising from 4.3% of pregnancies in 2014 to a substantial 16.8% in 2023.
Understanding why disruption in sterol biosynthesis exerts profound effects on neurodevelopment requires delving into the role of cholesterol in fetal growth. Cholesterol is indispensable for the development of the fetal brain and other critical organs, serving as a fundamental component of cell membranes, precursor for steroid hormone synthesis, and a modulator of signaling pathways guiding neural differentiation. The fetal brain itself commences autonomous sterol production around 19 to 20 weeks of gestation, a period critical for synaptogenesis and circuit formation. Intriguingly, inherited mutations affecting this pathway result in devastating developmental disorders such as Smith-Lemli-Opitz syndrome, where as many as 75% of affected children exhibit ASD symptomatology. The present study suggests that pharmacologic interference of the same pathway may recapitulate aspects of this vulnerability, underscoring the delicate balance required for healthy brain maturation.
While the implicated medications are widely used and often essential for managing chronic conditions in pregnant individuals, these findings prompt a reevaluation of their safety profiles during gestation. The authors emphasize that the results should not instill fear or lead to abrupt cessation of prescribed treatments without medical guidance; rather, they advocate for heightened vigilance among healthcare providers. The study articulates a pressing need to scrutinize the biochemical footprints of existing and new pharmaceuticals on sterol metabolism, especially as prescribing patterns evolve and the prevalence of polypharmacy in pregnancy increases.
The implications extend beyond individual prescriptions to public health strategy. The researchers propose several critical avenues for future action, such as constructing an exhaustive pharmacopeia identifying sterol-inhibiting agents and integrating sterol metabolism assessments into the drug development pipeline. Enhanced education for clinicians about the neurodevelopmental risks associated with sterol disruption during pregnancy could inform prescription decisions, facilitating safer alternatives when available or minimizing combined exposures. Additionally, identifying pregnant individuals with inherent genetic susceptibilities in sterol metabolism might tailor risk mitigation efforts, allowing for personalized therapeutic strategies.
This landmark investigation represents a significant advancement in the field of perinatal pharmacology and neurodevelopmental research. By leveraging the unprecedented scale of electronic health record data, the UNMC team transcended traditional research boundaries, highlighting a biochemical mechanism that may underlie a portion of ASD etiology linked to environmental exposures. Their findings beckon a multidisciplinary response involving molecular biology, clinical pharmacology, genetics, and public health and may catalyze innovative approaches to safeguarding fetal brain health in the context of necessary maternal medical treatment.
The study also draws attention to broader biomedical and ethical considerations. Balancing maternal health needs with fetal safety requires nuanced clinical judgment, informed by emerging evidence such as this. It underscores the importance of comprehensive prenatal care and the integration of precision medicine principles that account for drug mechanisms at the biochemical level. Ultimately, the research illuminates a path toward more informed, safer medical prescribing during pregnancy, with the potential to diminish the burden of ASD and enhance childhood neurodevelopmental outcomes on a population scale.
As the scientific community digests these insights, there remains a clear imperative for further research. Investigations into the specific molecular disruptions caused by individual SBIMs, their dose-response relationships, timing of exposure during gestation, and interaction with genetic variants will be critical. Moreover, exploring potential protective strategies or adjunct therapies to counteract sterol biosynthesis inhibition could open therapeutic avenues. This study marks a first but decisive step toward unraveling the complex interplay between prenatal environmental factors and long-term neurodevelopment.
UNMC’s leadership in this endeavor reflects their commitment to innovative, patient-centered research. The collaboration among pediatricians, biostatisticians, and neurodevelopment experts, supported by internal resources and foundations, showcases the power of interdisciplinary science to tackle pressing public health challenges. Their engagement with the Epic Cosmos platform exemplifies how large-scale digital health data can fuel groundbreaking discoveries with enduring impact.
In summary, the revelation that commonly prescribed sterol biosynthesis-inhibiting drugs during pregnancy may elevate autism risk invites a paradigm shift in perinatal pharmacotherapy. It underscores the necessity for scientific, clinical, and policy efforts to ensure that medications safeguarding maternal well-being do not inadvertently compromise fetal neurodevelopment. Continued vigilance, research, and innovation will be essential to unravel and mitigate these complex risks, ultimately driving progress toward healthier futures for both mothers and their children.
Subject of Research: People
Article Title: Study suggests link between prenatal exposure to certain medications and increased autism risk
News Publication Date: 16-Apr-2026
Web References: https://www.nature.com/articles/s41380-026-03610-7
Image Credits: Kiley Cruse and Chuck Koster
Keywords: Human health, Developmental disabilities, Autism spectrum disorder, Prenatal medication, Sterol biosynthesis inhibition, Cholesterol metabolism, Neurodevelopment, Perinatal pharmacology, Electronic health records, Public health
